Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Radaeli

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Drug Discovery Today|November 29, 2011
Therapeutic potential for novel ultra long-acting β2-agonists in the management of COPD: biological and pharmacological aspectsMario Malerba, Alessandro Radaeli, Jaymin B Morjaria
International Journal of Chronic Obstructive Pulmonary Disease|July 26, 2014
Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD--role of umeclidinium/vilanterolMario Malerba, Jaymin Bhagwanji Morjaria, Alessandro Radaeli
Chest|October 10, 2008
Usefulness of exhaled nitric oxide and sputum eosinophils in the long-term control of eosinophilic asthmaMario Malerba, Beatrice Ragnoli, Alessandro Radaeli, et al.
Internal and Emergency Medicine|October 4, 2011
COPD and the metabolic syndrome: an intriguing associationEnrico Clini, Ernesto Crisafulli, Alessandro Radaeli, et al.
International Journal of Environmental Research and Public Health|November 14, 2019
Determinants of Smoking Status in a Sample of Outpatients Afferent to a Tertiary Referral HospitalAlessandro Radaeli, Matteo Nardin, Danila Azzolina, et al.
Drug Discovery Today|September 21, 2014
Role of beta-blockers in patients with COPD: current perspectiveMario Malerba, Paolo Montuschi, Alessandro Radaeli, et al.
Expert Review of Respiratory Medicine|May 5, 2016
Vilanterol trifenatate for the treatment of COPDMario Malerba, Alessandro Radaeli, Paolo Montuschi, et al.
Frontiers in Pharmacology|May 6, 2021
Predictive Markers of Bronchial Hyperreactivity in a Large Cohort of Young Adults With Cough Variant AsthmaMario Malerba, Beatrice Ragnoli, Danila Azzolina, et al.
Pulmonary Pharmacology & Therapeutics|December 4, 2003
Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial)Mario Malerba, Antonio Ponticiello, Alessandro Radaeli, et al.
Rejuvenation Research|May 21, 2011
Age-related increase of airway neutrophils in older healthy nonsmoking subjectsPatrizia Pignatti, Beatrice Ragnoli, Alessandro Radaeli, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Drug Discovery Today|November 29, 2011
Therapeutic potential for novel ultra long-acting β2-agonists in the management of COPD: biological and pharmacological aspectsMario Malerba, Alessandro Radaeli, Jaymin B Morjaria
International Journal of Chronic Obstructive Pulmonary Disease|July 26, 2014
Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD--role of umeclidinium/vilanterolMario Malerba, Jaymin Bhagwanji Morjaria, Alessandro Radaeli
Chest|October 10, 2008
Usefulness of exhaled nitric oxide and sputum eosinophils in the long-term control of eosinophilic asthmaMario Malerba, Beatrice Ragnoli, Alessandro Radaeli, et al.
Internal and Emergency Medicine|October 4, 2011
COPD and the metabolic syndrome: an intriguing associationEnrico Clini, Ernesto Crisafulli, Alessandro Radaeli, et al.
International Journal of Environmental Research and Public Health|November 14, 2019
Determinants of Smoking Status in a Sample of Outpatients Afferent to a Tertiary Referral HospitalAlessandro Radaeli, Matteo Nardin, Danila Azzolina, et al.
Drug Discovery Today|September 21, 2014
Role of beta-blockers in patients with COPD: current perspectiveMario Malerba, Paolo Montuschi, Alessandro Radaeli, et al.
Expert Review of Respiratory Medicine|May 5, 2016
Vilanterol trifenatate for the treatment of COPDMario Malerba, Alessandro Radaeli, Paolo Montuschi, et al.
Frontiers in Pharmacology|May 6, 2021
Predictive Markers of Bronchial Hyperreactivity in a Large Cohort of Young Adults With Cough Variant AsthmaMario Malerba, Beatrice Ragnoli, Danila Azzolina, et al.
Pulmonary Pharmacology & Therapeutics|December 4, 2003
Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial)Mario Malerba, Antonio Ponticiello, Alessandro Radaeli, et al.
Rejuvenation Research|May 21, 2011
Age-related increase of airway neutrophils in older healthy nonsmoking subjectsPatrizia Pignatti, Beatrice Ragnoli, Alessandro Radaeli, et al.
Pageof 3